Factbox-Global pharma companies that have publicly announced Trump drug pricing agreements

Sept 1 (Reuters) – U.S. President Donald Trump has struck drug-pricing deals with more than 20 pharmaceutical companies in a bid to reduce prescription costs that are often nearly three times higher than those paid by patients in other developed countries.

The first wave of deals, struck with 17 major drugmakers starting last year, included commitments to “most-favoured-nation” pricing, sales through the TrumpRx.gov platform, and U.S. investment pledges in exchange for tariff relief.

A second wave, announced in late August, added agreements with nine companies, including some smaller biotechs, offering drugs to state Medicaid programs at most-favoured-nation prices.

Small and mid-size companies, which have different business models than big pharma companies, had been slow to sign onto drug-pricing deals.

Here are details on the deals:

PFIZER

The company in September agreed to lower prescription drug prices for American patients, including discounts of up to 85% through TrumpRx.gov.

Pfizer said the majority of its primary care treatments and some select brands, such as rheumatoid arthritis drug Xeljanz, dermatitis drug Eucrisa and post-menopausal osteoporosis medicine Duavee, will be offered at average savings of 50%, which can be as high as 85%.

JOHNSON & JOHNSON

Drugmaker J&J in January agreed to lower drug prices for American patients, including through the TrumpRx.gov platform.

Specific terms of the agreement were not disclosed, including details on revised drug prices or which medicines are covered.

ASTRAZENECA

AstraZeneca in October agreed to lower prescription drug prices for American patients, including discounts of up to 80% through TrumpRx.gov.

NOVO NORDISK

Weight-loss drug maker Novo Nordisk in November agreed to reduce prices for its semaglutide medicines, including Wegovy and Ozempic, for American patients through the government’s Medicare, Medicaid and a direct-to-patient cash channel.

Prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

Novo Nordisk will also provide widely used insulin products, including NovoLog and Tresiba, at $35 per month through TrumpRx.

ELI LILLY

Eli Lilly in November agreed to offer Medicare beneficiaries its obesity medicines Zepbound and orforglipron, branded as Foundayo, at no more than $50 per month, with additional discounts for self-pay patients through LillyDirect.

The Zepbound multidose pen will be available at $299 per month at the lowest dose, with additional doses priced up to $449, while Foundayo will be available starting at $149 per month at its lowest dose through LillyDirect.

Lilly will also offer Emgality, a migraine treatment, at $299 per pen, and Trulicity, a diabetes medicine, at $389 per month through TrumpRx.

ABBVIE

AbbVie in January agreed to lower drug prices through Medicaid and expand direct-to-patient offerings via TrumpRx for medicines, including Humira and Synthroid.

BRISTOL MYERS SQUIBB

Bristol Myers Squibb said in December it will provide its blockbuster blood-thinner Eliquis to Medicaid for free as part of its deal with the Trump administration.

It also agreed to donate more than seven tons of active pharmaceutical ingredient for Eliquis.

GILEAD SCIENCES

Gilead Sciences said in December it will provide select medicines to treat HIV, hepatitis C, hepatitis B and COVID-19 at a discounted price for Medicaid beneficiaries.

It agreed to price future medicines at parity with other key developed nations and make its hepatitis C treatment, Epclusa, available at a discounted cash price through TrumpRx and its own direct-to-patient program.

EMD SERONO

Trump and Merck KGaA unit EMD Serono said in October the German company would sell its fertility treatments, including Gonal-f, Ovidrel and Cetrotide, directly to consumers with a combined discount of 84% off list price if three of them were used in IVF.

It would offer all new drugs launched in the U.S. at the prices it charges in other developed countries.

MERCK

U.S. drugmaker Merck in December said it will sell diabetes drugs Januvia, Janumet and Janumet XR — set to face generic competition next year — directly to U.S. consumers at about 70% off list prices.

If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels, including TrumpRx.

ROCHE

Roche unit Genentech said in December it would lower prices for many of its medicines under Medicaid, comparable to those available in other wealthy countries.

It also agreed to make its influenza medicines available through TrumpRx.gov and through its own direct-to-patient program.

NOVARTIS

Novartis said in December it would launch new drugs in the U.S. at prices comparable to other developed countries.

It also agreed to make multiple sclerosis drug Mayzent as well as cancer drugs Rydapt and Tabrecta available through its direct-to-patient platform and TrumpRx.gov.

AMGEN

Amgen said it will add cholesterol drug Repatha at a monthly price of $239, migraine drug Aimovig, and arthritis treatment Amjevita at $299 a month to its direct-to-patient program, which is 60% to 80% off list price.

SANOFI

Sanofi said in December it will offer lower-cost medicines via TrumpRx and other direct-to-patient platforms, with average savings of about 70% on treatments for infections, heart disease, and diabetes.

It also agreed to align the Medicaid price of several medicines with those in other high-income countries.

GSK

GSK in December agreed to make most of its inhaled respiratory medicines and other drugs available to patients on a direct-to-patient platform with savings of up to 66%.

It also agreed to lower the price of certain medicines in Medicaid and launch new drugs with a “more balanced pricing approach” across developed nations.

BOEHRINGER INGELHEIM

Boehringer Ingelheim said in December it would make its medicines available through TrumpRx.gov at discounted prices.

REGENERON

Regeneron in April agreed to cut prices on its existing and future medicines sold through Medicaid and to lower the price of its cholesterol drug Praluent to $225 from $537 for patients buying directly through TrumpRx.

It will also offer its newly approved gene therapy for a rare form of hearing loss, Otarmeni, for free to eligible U.S. patients.

MIDCAPS/SMALLER DRUGMAKERS:

ASTELLAS

Japan’s Astellas agreed to lower Medicaid drug prices in line with other developed countries and donate 25 kg of transplant drug tacrolimus to a U.S. strategic reserve.

KYOWA KIRIN

Japan’s Kyowa Kirin will provide discounts to Medicaid patients and align overseas drug pricing more closely with U.S. levels in return for potential tariff relief.

CSL

Australia’s CSL will offer discounted medicines to Medicaid patients and invest $1.5 billion in Illinois manufacturing, creating more than 1,100 jobs, in return for clarity on its exposure to U.S. drug-pricing measures and certain pharmaceutical tariffs.

BRIDGEBIO

BridgeBio will broaden Medicaid access to its heart drug Attruby and reduce costs under an agreement that the company said would help it avoid future pricing mandates.

SUN PHARMACEUTICAL

India’s Sun Pharma will offer discounted medicines to Medicaid patients and future therapies in return for a two-year delay in potential U.S. tariffs on its innovative drugs.

UCB

Belgium’s UCB reached an agreement to offer more balanced drug pricing and join in a Medicaid drug-pricing program, expand manufacturing investment in the U.S., donate supplies of its epilepsy drug Keppra to the national stockpile.

This would exempt the company from potential pharmaceutical tariffs and future price mandates.

BEONE MEDICINES

BeOne agreed to expand Medicaid access to its cancer medicines, invest further in U.S. manufacturing, and secure an exemption from potential pharmaceutical tariffs.

ALCON

Switzerland’s Alcon also reached an agreement with the Trump administration, though no specifics were disclosed.

(Reporting by Kamal Choudhury, Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Shreya Biswas and Anil D’Silva)